STCube

STCube EBITDA Growth YoY

The Year-over-Year EBITDA Growth of STCube (052020.KQ) as of Nov 1, 2026 is -9.15 %. In the previous year, Year-over-Year EBITDA Growth was 14.40 % — a change of -163.52% (lower).

EBITDA Growth YoY

-9.15 %

YoY

-163.52%

Last updated:

Year-over-Year EBITDA Growth of STCube is 2025 -9.15 % . Year-over-Year EBITDA Growth of STCube was 2024 14.40 % . It decreases by -163.52% lower compared to the previous year.

The STCube EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
22.27 KRW
Jan 1, 2019
20.30 KRW
Jan 1, 2020
-39.80 KRW
Jan 1, 2021
-53.33 KRW
Jan 1, 2022
0.83 KRW
Jan 1, 2023
-38.42 KRW
Jan 1, 2024
14.40 KRW
Jan 1, 2025
-9.15 KRW
The STCube EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-9.15 %-163.52%
14.40 %-137.48%
-38.42 %-4,741.81%
0.83 %-101.55%
-53.33 %+33.98%
-39.80 %-296.05%
20.30 %-8.85%
22.27 %-104.12%
-540.70 %-1,196.81%
49.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Year-over-Year EBITDA Growth of STCube is -9.15 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth STCube since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — STCube

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — STCube